Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.